Leerink Swann Downgrades Par Pharmaceutical (PRX) to Market Perform; Not Expecting Mylan (MYL) To Up The Ante

Go back to Leerink Swann Downgrades Par Pharmaceutical (PRX) to Market Perform; Not Expecting Mylan (MYL) To Up The Ante